Jane Street Group LLC Buys New Position in Nexalin Technology, Inc. (NASDAQ:NXL)

Jane Street Group LLC acquired a new position in Nexalin Technology, Inc. (NASDAQ:NXL) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,304 shares of the company’s stock, valued at approximately $28,000. Jane Street Group LLC owned approximately 0.08% of Nexalin Technology at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Kingsview Wealth Management LLC bought a new position in shares of Nexalin Technology in the fourth quarter worth about $28,000. Northern Trust Corp bought a new stake in shares of Nexalin Technology during the 4th quarter worth approximately $36,000. XTX Topco Ltd bought a new stake in Nexalin Technology during the 4th quarter valued at $46,000. Finally, Geode Capital Management LLC raised its position in Nexalin Technology by 36.3% during the 4th quarter. Geode Capital Management LLC now owns 107,241 shares of the company’s stock valued at $296,000 after purchasing an additional 28,544 shares in the last quarter. Institutional investors own 0.65% of the company’s stock.

Nexalin Technology Price Performance

Shares of Nexalin Technology stock opened at $1.27 on Tuesday. The business has a 50 day simple moving average of $1.48 and a two-hundred day simple moving average of $2.46. Nexalin Technology, Inc. has a 12 month low of $0.53 and a 12 month high of $4.49. The stock has a market capitalization of $21.82 million, a P/E ratio of -1.98 and a beta of 4.00.

Nexalin Technology (NASDAQ:NXL) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.05). Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million.

Analyst Ratings Changes

Separately, Maxim Group upgraded Nexalin Technology from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, March 24th.

About Nexalin Technology

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.